Circulating tumor gangliosides enhance platelet activation

Area of Science:

• Biochemistry
• Oncology
• Hematology

Background:

• Gangliosides are implicated in tumor formation and neuroblastoma progression.
• Platelet activation is a potential factor in cancer metastasis.

Purpose of the Study:

• To investigate the effect of tumor-derived gangliosides in neuroblastoma patient serum on platelet function.
• To determine if shed gangliosides contribute to platelet activation and metastasis.

Main Methods:

• Platelet aggregation and adenosine triphosphate (ATP) release assays were performed using normal platelets incubated with patient or normal serum.
• Lipoprotein fractions from patient and normal serum were isolated and their effects on platelet ATP release were assessed.
• Purified gangliosides from patient serum and neuroblastoma cell lines were tested for their ability to induce platelet ATP release.

Main Results:

• Patient serum containing tumor gangliosides significantly increased platelet aggregation and ATP release compared to normal serum.
• The lipoprotein fraction from patient serum enhanced platelet ATP release, while depleted fractions and normal serum fractions did not.
• Purified neuroblastoma gangliosides, at concentrations as low as 0.5 μmol/L, significantly increased platelet ATP release.

Conclusions:

• Neuroblastoma patient serum, specifically its ganglioside and lipoprotein components, enhances platelet activation.
• Tumor-derived gangliosides are potent activators of platelets, suggesting a mechanism for their role in neuroblastoma metastasis.
• These findings highlight the pro-metastatic potential of shed tumor gangliosides in neuroblastoma.